BioCentury | May 9, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and chicken embryo studies suggest inhibiting FZD8 could help treat prostate cancer. In patient samples, levels of FZD8 were higher in tumors than in adjacent normal prostate tissue....
BioCentury | May 2, 2018
Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Tool compounds; structural analyses Structural analysis of a peptide inhibitor bound to the cysteine-rich domain (CRD) of FZD7 could guide the development of small molecule FZD7 inhibitors, and the peptide could be used to...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BioCentury | Apr 10, 2017
Clinical News

OncoMed's demcizumab fails Phase II pancreatic cancer trial

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $3.21 (37%) to $5.55 on Monday after reporting that demcizumab ( OMP-21M18 ) missed the primary endpoint in the Phase II YOSEMITE trial to treat metastatic pancreatic cancer in the first-line setting....
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

...INDICATION: Pancreatic cancer; colorectal cancer Cell culture, mouse and patient sample studies suggest anti- FZD5 mAbs...
...other RNF43 -mutant cancers. In four RNF43-mutant human pancreatic ductal adenocarcinoma (PDAC) cell lines, two anti-FZD5...
...compared with control IgG. In a xenograft mouse model of RNF43-mutant PDAC, one of the anti-FZD5...
BioCentury | Nov 17, 2016
Clinical News

Vantictumab: Interim Ph Ib data

Interim data from 21 evaluable patients in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV vantictumab on days 1 and 15 of each 28-day cycle plus Abraxane nab-paclitaxel and gemcitabine led to an...
BioCentury | Nov 17, 2016
Clinical News

Ipafricept: Interim Ph Ib data

Interim data from 18 evaluable patients in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV ipafricept on days 1 and 15 of each 28-day cycle plus Abraxane nab-paclitaxel and gemcitabine led to an...
BioCentury | Nov 15, 2016
Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Cell culture and mouse studies suggest inhibiting FZD1 , FZD2 and/or FZD7 could help treat Clostridium difficile infection (CDI). In a human cell line treated with TcdB , knockout of FZD1, FZD2 or FZD7 decreased...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
BioCentury | Jun 6, 2016
Clinical News

Ipafricept: Phase Ib data

Top-line data from 17 evaluable patients with recurrent platinum-sensitive ovarian cancer in an open-label, dose-escalation, U.S. Phase Ib trial showed that 2, 4, 5 and 10 mg/kg IV ipafricept every 3 weeks plus carboplatin and...
Items per page:
1 - 10 of 41